Synchron Secures $200M to Fuel BCI Commercialization

Brain-computer interface firm Synchron has secured a $200 million Series D funding round, propelling its expansion in key markets like New York and San Francisco. The investment will be used to advance clinical studies and enhance commercialization efforts, marking a significant milestone for neurotechnology. 💰 🧠 Synchron’s flagship product, the Stentrode, offers non-invasive brain-computer synchronization capabilities, and this funding aims to further develop and expand its applications.